Recent evidence suggests that AKI in COVID-19 populations occurs as a result of SARS-CoV-2-specific factors such as virus-mediated injury, abnormal inflammatory response (cytokine storm), angiotensin II pathway activation, microangiopathy and hypercoagulative condition [9]. This evidence concerns the gene AGT and COVID-19.